NCT02100371View on ClinicalTrials.gov

Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome

NACompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Basal Cell Nevus Syndrome
Interventions
DRUG

BMS-833923

BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002.

Trial Locations (1)

M5G 2M9

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT02100371 - Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome | Biotech Hunter | Biotech Hunter